Investigational Drug Survodutide Demonstrates Significant Weight Loss in Obesity and Type 2 Diabetes

New research in The New England Journal of Medicine shows that once-weekly survodutide, a dual agonist, led to significantly greater weight reduction in adults with obesity and type 2 diabetes compared to placebo. Participants on higher doses achieved mean weight changes of –8.2% and –9.8% at week 76, highlighting survodutide's potential as an effective new weight management therapy for this patient population, adding to the growing class of GLP-1 related drugs.